Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis
Autor: | Katie L. Kunze, Tania Jain, Daniel K. Partain, William J. Hogan, M'hamed Temkit, Veena Fauble, Lisa Z. Sproat, Vivek Roy, Jeanne Palmer, Mrinal S. Patnaik, Pierre Noel, James L. Slack, Jose F. Leis, Nandita Khera, Ruben A. Mesa |
---|---|
Rok vydání: | 2018 |
Předmět: |
Adult
Male medicine.medical_specialty Transplantation Conditioning medicine.medical_treatment CD33 Graft vs Host Disease Antineoplastic Agents Hematopoietic stem cell transplantation Chimerism Gastroenterology Article 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Internal medicine medicine Humans Transplantation Homologous Myelofibrosis Busulfan Melphalan Survival analysis Aged Transplantation business.industry Hematopoietic Stem Cell Transplantation Hematology Middle Aged Myeloablative Agonists medicine.disease Carmustine Survival Analysis Fludarabine Primary Myelofibrosis 030220 oncology & carcinogenesis Cohort Female Stem cell business Vidarabine 030215 immunology medicine.drug |
Zdroj: | Bone Marrow Transplant |
ISSN: | 1476-5365 0268-3369 |
Popis: | The aim of this study is to compare clinical outcomes of patients who underwent allogeneic stem cell transplantation (HCT) for myelofibrosis with reduced intensity conditioning (RIC) using either Busulfan Fludarabine (BuFlu), Fludarabine Bis-chlorethyl-nitroso-urea/ carmustine Melphalan (FBM) or Fludarabine Melphalan (FluMel) regimens. Sixty-one patients were identified who underwent HCT with one of these RIC regimens. Overall survival (OS) was not different in the 3 groups. However, 100% donor chimerism was seen in more frequently at day +30 and day +100 in patients who received FBM or FluMel than BuFlu, in both CD3 and CD33 fractions. For instance, 100% donor chimerism in CD33 fraction was present in 100% patients in FBM cohort, 90% in FluMel cohort while 44% in BuFlu cohort at day +100. Acute graft-versus host disease, grade 2-4 and grade 3-4, was not statistically different in the 3 groups (BuFlu 47 and 35%, FBM 68 and 27%, FluMel 68 and 46%; p = 0.31 and 0.45). Relapses and non-relapse mortality was also not statistically significantly different. Our study shows similar OS with these 3 RIC regimens in myelofibrosis; although donor chimerism at day +30 and day +100 was better in patients who received FBM and FluMel. |
Databáze: | OpenAIRE |
Externí odkaz: |